Researchers evaluated the effect of denosumab on bone mineral density loss in patients with glucocorticoid-induced osteoporosis.
In 2018, 27.5 percent of older adults reported falling at least once in the previous year, with 10.2 percent reporting an injury from a fall.
Researchers determined the effects of zoledronic acid on knee cartilage volume loss in knee osteoarthritis and bone marrow lesions.
Factors during gestation and infancy may impact bone health in young adulthood.
Given the limited data is available on bone health of patients with NMOSD-AQP4, researchers aimed to investigate their risk for fracture and bone loss.
Researchers evaluated the effects of follow-up therapy after denosumab discontinuation on bone resorption, bone mineral density, and clinical fracture risk.
Bone microarchitecture and strength are reduced in women living with HIV, and tenofovir treatment may contribute to bone deficits.
A recently published report describes the case of a 61-year-old male patient who experienced antacid-induced hypercalcemia and highlights the importance of performing thorough medication reconciliation.
Inhibition of sclerostin with romosozumab may increase cardiovascular risk.
Researchers examined the association between fractures and Parkinson disease during the prodromal period.
Individuals with diabetes have an increased risk for hip and nonvertebral fractures.